SCM
REGN icon

SCS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SCS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Hold
471
– – ﹤0.01% 421
2026
Q1 		$364K Buy
471
+1
+0.2% +$766 ﹤0.01% 386
2025
Q4 		$363K Sell
470
-2
-0.4% -$1.36K ﹤0.01% 406
2025
Q3 		$265K Buy
+472
New +$267K ﹤0.01% 466

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCS Capital Management's REGN Position: Q2 2026 in Review

SCS Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 471 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

SCS Capital Management first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $364K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • SCS Capital Management held 471 shares of Regeneron Pharmaceuticals worth $294K as of Q2 2026.
  • SCS Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #421 holding.
  • SCS Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • SCS Capital Management's Regeneron Pharmaceuticals position peaked at $364K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.